Emerging advancements in protein biotherapeutics are driving the need for more sensitive and accurate bioanalytical methods for their quantification. Serving as an orthogonal technology to the traditional ligand binding assays (LBAs), LC-MS has been routinely adopted for quantitative measurement of protein levels in bioanalytical laboratories. While various MS approaches have been investigated by researchers, bottom-up workflows using targeted LC-MRM strategy remain the most common. Here, to leverage selectivity, accurate mass spectrometry was used to quantify a series of signature peptides in rat plasma. The novel QTOF mass spectrometer involves improvements in MS/MS sampling efficiency with the use of a Zeno trap which enables greater sensitivity for quantification. In addition, an overview of the fundamental steps to develop a highly sensitive and selective quantitative assay for signature peptides will be presented.
In this webinar, Dr. Xin Zhang, Senior Application Scientist at SCIEX, presented an assay development method using accurate mass spectrometry to quantify a series of signature peptides in rat plasma. She also provided an overview of the fundamental steps to develop a highly sensitive and selective quantitative assay for signature peptides.
Who should watch:
Scientists and lab directors at:
• Bioanalytical research labs
• Core labs
• Pharmaceutical development labs
• CROs
What you will learn:
• The fundamental steps to develop a quantitative assay for signature peptides
• An assay development example using high-resolution accurate mass spectrometry
• How to address the sensitivity challenges in peptide quantification in a complex matrix
• How to achieve better selectivity between target peptide versus matrix-derived interferences and general high background effects
To secure your place, watch free now.
